🇺🇸 FDA
Pipeline program

RD13-02

IIT2024081

Phase 1 mab active

Quick answer

RD13-02 for Severe Aplastic Anemia is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Severe Aplastic Anemia
Phase
Phase 1
Modality
mab
Status
active

Clinical trials